{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:51:02Z","timestamp":1770486662082,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:00:00Z","timestamp":1551657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:00:00Z","timestamp":1551657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s10792-019-01088-7","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T10:59:59Z","timestamp":1551697199000},"page":"2697-2705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Assessment of vascular leakage and its development with FFA among patients treated with intravitreal anti-VEGF due to aggressive posterior ROP"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5535-264X","authenticated-orcid":false,"given":"Dilbade Y\u0131ld\u0131z","family":"Ekinci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asli Deger","family":"Vural","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadik Etka","family":"Bayramoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail Umut","family":"Onur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulsum Oya","family":"Hergunsel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,4]]},"reference":[{"issue":"1","key":"1088_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/pr.2013.205","volume":"74","author":"H Blencowe","year":"2013","unstructured":"Blencowe H, Lawn JE, Vazquez T et al (2013) Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res 74(1):35\u201349","journal-title":"Pediatr Res"},{"key":"1088_CR2","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684\u20131694","journal-title":"Arch Ophthalmol"},{"key":"1088_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","volume":"106","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1988","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group (1988) Multicenter trial of cryotherapy for retinopathy: preliminary results. Arch Ophthalmol 106:471\u2013479","journal-title":"Arch Ophthalmol"},{"key":"1088_CR4","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM et al (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855\u2013859","journal-title":"Ophthalmology"},{"key":"1088_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4103\/0301-4738.29505","volume":"55","author":"PK Shah","year":"2007","unstructured":"Shah PK, Narendran V, Tawansy KA et al (2007) Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 55:75\u201376","journal-title":"Indian J Ophthalmol"},{"key":"1088_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3928\/15428877-20070501-09","volume":"38","author":"A Travassos","year":"2007","unstructured":"Travassos A, Teixeira S, Ferreira P et al (2007) Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 38:233\u2013237","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"1088_CR7","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","volume":"28","author":"HA Mintz-Hittner","year":"2008","unstructured":"Mintz-Hittner HA, Kuffel RR Jr (2008) Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 28:831\u2013838","journal-title":"Retina"},{"key":"1088_CR8","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","volume":"245","author":"EJ Chung","year":"2007","unstructured":"Chung EJ, Kim JH, Ahn HS, Koh HJ (2007) Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 245:1727\u20131730","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1088_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jaapos.2009.10.011","volume":"14","author":"JC Law","year":"2010","unstructured":"Law JC, Recchia FM, Morrison DG et al (2010) Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS 14:6\u201310","journal-title":"J AAPOS"},{"key":"1088_CR10","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","volume":"28","author":"GA Lalwani","year":"2008","unstructured":"Lalwani GA, Berrocal AM, Murray TG et al (2008) Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 28:S13\u2013S18","journal-title":"Retina"},{"issue":"6","key":"1088_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3928\/01913913-20160727-01","volume":"53","author":"P Larraiaga-Fragoso","year":"2016","unstructured":"Larraiaga-Fragoso P, Peralta J, Bravo-Ljubetic L, Pastora N, Abelairas Gomez J (2016) Intravitreal bevacizumab for zone II retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 53(6):375\u2013382","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"1088_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3\u2009+\u2009retinopathy of prematurity. N Engl J Med 364:603\u2013615","journal-title":"N Engl J Med"},{"key":"1088_CR13","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.12659\/MSM.897095","volume":"22","author":"SD Nicoara","year":"2016","unstructured":"Nicoara SD, \u015etefanu\u0163 AC, Nascutzy C, Zaharie GC, Toader LE, Drugan TC (2016) Regression rates following the treatment of aggressive posterior retinopathy of prematurity with bevacizumab versus laser: 8-year retrospective analysis. Med Sci Monit 22:1192\u20131209","journal-title":"Med Sci Monit"},{"key":"1088_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","volume":"98","author":"SG Tahija","year":"2014","unstructured":"Tahija SG, Hersetyati R, Lam GC, Kusaka S, McMenamin PG (2014) Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol 98:507\u2013512","journal-title":"Br J Ophthalmol"},{"key":"1088_CR15","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","volume":"121","author":"D Lepore","year":"2014","unstructured":"Lepore D, Quinn GE, Molle F et al (2014) Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology 121:2212\u20132219","journal-title":"Ophthalmology"},{"issue":"8","key":"1088_CR16","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.ophtha.2015.04.023","volume":"122","author":"MA Klufas","year":"2015","unstructured":"Klufas MA, Patel SN, Ryan MC, Patel Gupta M, Jonas KE et al (2015) Influence of fluorescein angiography on the diagnosis and management of retinopathy of prematurity. Ophthalmology 122(8):1601\u20131608","journal-title":"Ophthalmology"},{"key":"1088_CR17","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"The Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"The Committee for the Classification of Retinopathy of Prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991\u2013999","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"1088_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","volume":"37","author":"B Lorenz","year":"2017","unstructured":"Lorenz B, Stieger K, Jager M, Mais C, Stieger S, Andrassi-Darida M (2017) Retinal vascular development with 0.312\u00a0mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity. A longitudinal fluorescein angiographic study. Retina 37(1):97\u2013111","journal-title":"Retina"},{"key":"1088_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1586\/17469899.2015.1007128","volume":"10","author":"B Lorenz","year":"2015","unstructured":"Lorenz B, Stieger K (2015) Retinopathy of prematurity-recent developments in diagnosis and treatment. Expert Rev Ophthalmol 10:167\u2013182","journal-title":"Expert Rev Ophthalmol"},{"key":"1088_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0161-6420(79)35437-9","volume":"86","author":"HM Hittner","year":"1979","unstructured":"Hittner HM, Rhodes LM, McPherson AR (1979) Anterior segment abnormalities in cicatricial retinopathy of prematurity. Ophthalmology 86:803\u2013816","journal-title":"Ophthalmology"},{"key":"1088_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaapos.2004.10.007","volume":"9","author":"L Trigler","year":"2005","unstructured":"Trigler L, Weaver RG Jr, O\u2019Neil JW et al (2005) Case series of angle-closure glaucoma after laser treatment for retinopathy of prematurity. J AAPOS 9:17\u201321","journal-title":"J AAPOS"},{"key":"1088_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1001\/archophthalmol.2011.143","volume":"129","author":"GE Quinn","year":"2011","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group, Quinn GE, Dobson V et al (2011) Visual field extent at 6\u00a0years of age in children who had high-risk prethreshold retinopathy of prematurity. Arch Ophthalmol 129:127\u2013132","journal-title":"Arch Ophthalmol"},{"key":"1088_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jaapos.2012.10.025","volume":"17","author":"GE Quinn","year":"2013","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group, Quinn GE, Dobson V et al (2013) Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings at 4 to 6\u00a0years of age. J AAPOS 17:124\u2013128","journal-title":"J AAPOS"},{"key":"1088_CR24","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL et al (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 132:1327\u20131333","journal-title":"JAMA Ophthalmol"},{"key":"1088_CR25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3928\/23258160-20160229-12","volume":"47","author":"LL Snyder","year":"2016","unstructured":"Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, Blair MP (2016) Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retina 47:280\u2013283","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"1088_CR26","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ et al (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130:1000\u20131006","journal-title":"Arch Ophthalmol"},{"key":"1088_CR27","doi-asserted-by":"publisher","first-page":"150.e1","DOI":"10.1016\/j.ajo.2012.06.010","volume":"155","author":"WC Wu","year":"2013","unstructured":"Wu WC, Kuo HK, Yeh PT et al (2013) An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. Am J Ophthalmol 155:150.e1\u2013158.e1","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"1088_CR28","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","volume":"38","author":"JM Garcia Gonzalez","year":"2018","unstructured":"Garcia Gonzalez JM, Snyder L, Blair M, Rohr A, Shapiro M, Greenwald M (2018) Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity. Retina 38(4):764\u2013772","journal-title":"Retina"},{"issue":"3","key":"1088_CR29","first-page":"53","volume":"25","author":"V Purcaro","year":"2012","unstructured":"Purcaro V, Baldascino A, Papacci P et al (2012) Fluorescein angiography and retinal vascular development in premature infants. J Matern Fetal Neonatal Med 25(3):53\u201356","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"2","key":"1088_CR30","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","volume":"125","author":"D Lepore","year":"2017","unstructured":"Lepore D, Quinn GE, Molle F et al (2017) Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology 125(2):218\u2013226","journal-title":"Ophthalmology"},{"issue":"10","key":"1088_CR31","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.ophtha.2016.06.055","volume":"123","author":"BC Toy","year":"2016","unstructured":"Toy BC, Schachar IH, Tan GS, Moshfeghi DM (2016) Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity. Ophthalmology 123(10):2166\u20132175","journal-title":"Ophthalmology"},{"key":"1088_CR32","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00417-013-2321-8","volume":"251","author":"LC Zepeda-Romero","year":"2013","unstructured":"Zepeda-Romero LC, Oregon-Miranda AA, Lizarraga-Barron DS, Gutierrez-Camarena O, Meza-Anguiano A, Gutierrez-Padilla JA (2013) Early retinopathy of prematurity findings identified with fluorescein angiography. Graefes Arch Clin Exp Ophthalmol 251:2093\u20132097","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"updated-by":[{"DOI":"10.1007\/s10792-019-01220-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:00:00Z","timestamp":1573862400000}}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-019-01088-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-019-01088-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-019-01088-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T05:28:34Z","timestamp":1596000514000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-019-01088-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,4]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1088"],"URL":"https:\/\/doi.org\/10.1007\/s10792-019-01088-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10792-019-01220-7","asserted-by":"object"}]},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,4]]},"assertion":[{"value":"15 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original publication, the authors\u2019 affiliations were published incorrectly.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}